Cargando…

Evaluation of the roles and regulatory mechanisms of PD-1 target molecules in NSCLC progression

BACKGROUND: Targeted programmed cell death protein 1 (PD-1) therapy could effectively improve the long-term prognosis of patients with non-small cell lung cancer (NSCLC). The role of PD-1 targets in the progression of NSCLC has not been fully revealed. METHODS: The differentially expressed genes (DE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yun-Qiang, Yuan, Ye, Zhang, Jun, Lin, Cheng-Yi, Guo, Jia-Long, Liu, Hua-Song, Guo, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350711/ https://www.ncbi.nlm.nih.gov/pubmed/34430609 http://dx.doi.org/10.21037/atm-21-2963

Ejemplares similares

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

The roles of risk model based on the 3-XRCC genes in lung adenocarcinoma progression
por: Zhang, Qun-Xian, et al.
Publicado: (2021)

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC
por: Jiang, Li, et al.
Publicado: (2019)

PD‐L1/p‐STAT3 promotes the progression of NSCLC cells by regulating TAM polarization
por: Zhang, Rui, et al.
Publicado: (2022)

PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment
por: Su, Qiang, et al.
Publicado: (2017)

Specific inhibitor of Notch-3 enhances the sensitivity of NSCLC cells to gemcitabine
por: Hu, Bi-Dan, et al.
Publicado: (2018)

SPDL1 Overexpression Is Associated With the 18F-FDG PET/CT Metabolic Parameters, Prognosis, and Progression of Esophageal Cancer
por: Liu, Hua-Song, et al.
Publicado: (2022)

Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization
por: Guo, Yan, et al.
Publicado: (2021)

miR-657 Targets SRCIN1 via the Slug Pathway to Promote NSCLC Tumor Growth and EMT Induction
por: Zhang, Yingqian, et al.
Publicado: (2022)

PD-1(+) IFN-γ(+) subset of CD8(+) T cell in circulation predicts response to anti–PD-1 therapy in NSCLC
por: Chen, Wenxiu, et al.
Publicado: (2023)

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?
por: Sternschuss, Michal, et al.
Publicado: (2020)

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
por: Zhang, Hao, et al.
Publicado: (2021)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy
por: Dong, Song, et al.
Publicado: (2010)

LncRNA SNHG14 contributes to the progression of NSCLC through miR‐206/G6PD pathway
por: Zhao, Lin, et al.
Publicado: (2020)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Case Report: An “Immune-Cold” EGFR Mutant NSCLC With Strong PD-L1 Expression Shows Resistance to Chemo-Immunotherapy
por: Zhao, Qian, et al.
Publicado: (2022)

PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance
por: Zhang, Yan, et al.
Publicado: (2017)

Repression of YAP by NCTD disrupts NSCLC progression
por: Guo, Jiwei, et al.
Publicado: (2016)

Small Molecule Inhibitors Targeting Activator Protein 1 (AP-1): Miniperspective
por: Ye, Na, et al.
Publicado: (2014)

Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles
por: Guzik, Katarzyna, et al.
Publicado: (2019)

SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
por: Chen, Yu, et al.
Publicado: (2020)

Radiotherapy combined with PD‐1/PD‐L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges
por: Chen, Zi‐Ying, et al.
Publicado: (2022)

Research progress on the impact of radiation on TKI resistance mechanisms in NSCLC
por: Zhuang, Hongqing
Publicado: (2018)

HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC
por: Mei, Jie, et al.
Publicado: (2022)

Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials
por: Zhou, Guo-Wu, et al.
Publicado: (2016)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
por: Nie, Wei, et al.
Publicado: (2022)

Targeting Pyruvate Carboxylase by a Small Molecule Suppresses Breast Cancer Progression
por: Lin, Qingxiang, et al.
Publicado: (2020)

Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance
por: Schrank, Zachary, et al.
Publicado: (2018)

Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets
por: Bajbouj, Khuloud, et al.
Publicado: (2021)

The Regulatory Network and Potential Role of LINC00973-miRNA-mRNA ceRNA in the Progression of Non-Small-Cell Lung Cancer
por: Guo, Qiang, et al.
Publicado: (2021)

Research Progress on Therapeutic Targeting of Cancer-Associated Fibroblasts to Tackle Treatment-Resistant NSCLC
por: Li, Chenxin, et al.
Publicado: (2022)

Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)

High endothelial venules predict response to PD-1 inhibitors combined with anti-angiogenesis therapy in NSCLC
por: Ye, Dafu, et al.
Publicado: (2023)

Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC
por: Chen, Jing, et al.
Publicado: (2021)

Approaching the Dimerization Mechanism of Small Molecule Inhibitors Targeting PD-L1 with Molecular Simulation
por: Liang, Jianhuai, et al.
Publicado: (2023)

Expression of PD-1 Molecule on Regulatory T Lymphocytes in Patients with Insulin-Dependent Diabetes Mellitus
por: Perri, Valentina, et al.
Publicado: (2015)

Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
por: Yang, Bo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_r1jfnoo967ogjl3sulfo6v4urg